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Abstract
Objective: To analyze the microRNA profile in serum of patients with Adult
Onset Pompe disease (AOPD). Methods: We analyzed the expression of 185
microRNAs in serum of 15 AOPD patients and five controls using microRNA
PCR Panels. The expression levels of microRNAs that were deregulated were
further studied in 35 AOPD patients and 10 controls using Real-Time PCR.
Additionally, the skeletal muscle expression of microRNAs which showed signif-
icant increase levels in serum samples was also studied. Correlations between
microRNA serum levels and muscle function test, spirometry, and quantitative
muscle MRI were performed (these data correspond to the study NCT01914536
at ClinicalTrials.gov). Results: We identified 14 microRNAs that showed differ-
ent expression levels in serum samples of AOPD patients compared to controls.
We validated these results in a larger cohort of patients and we found increased
levels of three microRNAs, the so called dystromirs: miR-1-3p, miR-133a-3p,
and miR-206. These microRNAs are involved in muscle regeneration and the
expression of these was increased in patients’ muscle biopsies. Significant corre-
lations between microRNA levels and muscle function test were found. Inter-
pretation: Serum expression levels of dystromirs may represent additional
biomarkers for the follow-up of AOPD patients.
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Introduction
Pompe disease is an autosomal recessive disorder pro-
duced by mutations in the GAA gene that encodes for the
lysosomal enzyme acid alpha-glucosidase.1 This enzyme is
essential for the degradation of glycogen to glucose in
lysosomes.2 Mutations in the GAA gene cause absence or
deficiency of the enzyme leading to an accumulation of
glycogen in the lysosomes of several tissues particularly
cardiac, skeletal, and smooth muscle.3
Patients are classified as infantile (IOPD) or adult onset
Pompe disease (AOPD) depending on the age at onset of
symptoms.3 Classic IOPD patients have a rapidly progres-
sive disorder characterized by hypotonia, muscle weak-
ness, respiratory insufficiency, and hypertrophic
cardiomyopathy that lead patients to death before the first
year of life if untreated.4 AOPD patients have a more
heterogeneous clinical picture ranging from asymptomatic
HyperCKemia to weakness involving limb, axial, and res-
piratory muscles.5 Natural history studies have shown that
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AOPD is a slowly progressive disorder in which most of
the patients will present moderate to severe motor dis-
ability developing respiratory insufficiency and needing
noninvasive ventilation.6
Enzyme replacement therapy (ERT) with recombinant
alpha-glucosidase has changed natural history of the dis-
ease. In infantile patients, the treatment reduces the risk of
death improving cardiomyopathy and respiratory func-
tion.7,8 In AOPD patients, ERT improves and stabilizes
muscle function for a period of 2–3 years and afterwards
motor function slowly deteriorates9. There is an active dis-
cussion in the scientific community to know which tests
are most sensitive to identify changes in muscle perfor-
mance in AOPD patients after shorter periods of time10,11.
ERT is not approved for asymptomatic AOPD patients,
therefore these patients are being followed up using motor
function tests to identify changes in motor performance
that can support starting ERT. However it is possible that
irreversible muscle degeneration has already started with-
out influencing motor function. The identification of new
tools to follow-up progression of patients is one of the
hottest topics in the neuromuscular disorders field. In this
sense, quantitative muscle MRI (qMRI) has revealed to be
useful in several muscle disorders including Pompe dis-
ease.10,12 However, qMRI is not available in all centers
and, experience is needed to analyze it properly. Therefore,
other potential biomarkers are needed and serum mole-
cules such as microRNAs (miRNAs) could be useful.
A good biomarker should be detected in a sample that
can be obtained by minimally invasive procedures for the
patient. In this sense, serum or plasma is the best candi-
dates.13 miRNAs are small noncoding RNAs that exert their
effect on gene expression at the posttranscriptional level.
They have a length of approximately 22 nucleotides and, in
general, they inhibit protein synthesis or favor mRNA
degradation by binding to the UTR 3’ regions of those
mRNAs.14 Each miRNA regulates several target genes and a
given gene can be regulated by multiple miRNAs.15 miR-
NAs regulate several processes in skeletal muscle such as
muscle growth, atrophy, or regeneration. A specific group
of miRNAs, known as dystromirs are distinctly expressed in
serum of patients with muscle dystrophies. They have been
studied in Duchenne muscle dystrophy (DMD), Becker
muscle dystrophy of facio-scapulo-humeral muscle dystro-
phy (FSHD), but they have not been analyzed in serum
samples of patients with AOPD.16
In this project, we studied the serum expression of 190
miRNAs, including the so called dystromirs, in a group of 35
AOPD patients and 10 controls with the following aims: (1)
identify miRNAs that were up- or downregulated in AOPD
patients; (2) investigate if they could be used as biomarkers
of progression of the disease and; (3) understand the phys-
iopathology of muscle degeneration in Pompe disease.
Material and Methods
Patient and study design
This study is part of an ongoing prospective open-label
study in which we are following up a group of symp-
tomatic and nonsymptomatic AOPD patients using mus-
cle function tests, muscle MRI, and blood analysis. This
study has been registered in Clinicaltrials.gov (identifier
NCT01914536). The study was approved by The Ethics
Committee of Hospital de la Santa Creu i Sant Pau
(HSCSP) in Barcelona. All participants signed an appro-
priate informed consent form. All patients included ful-
filled the diagnostic criteria of Pompe disease established
by the European Pompe Consortium.17
We defined a patient as symptomatic when we identi-
fied muscle weakness in clinical examination using the
Medical Research Council score (MRC) or when Forced
Vital Capacity (FVC) seated was lower than 85%. We
included in this study a total of 35 patients: 21 symp-
tomatic patients treated with ERT, nine symptomatic
patients nontreated with ERT and five asymptomatic
patients. Clinical and genetic data of this Pompe cohort
have been previously published.10 Nontreated symp-
tomatic patients were visited before starting ERT. We also
studied 10 age and sex-matched healthy controls.
miRNA isolation in serum sample
Serum miRNAs were isolated from serum with DANA-
GENE microRNA and Cell free RNA Kit (DANAGEN,
Badalona, Spain) using MS2 RNA (Roche, Basel, Switzer-
land) as a carrier to improve the RNA isolation and
exogenous controls (Unisp2,4 and 5). miRNAs were
retrotranscribed into a cDNA with the miRCURY LNATM
Universal RT microRNA PCR (EXIQON).
Analysis of miRNA expression in serum
miRNA expression studies consisted two different phases:
discovery and validation. For the discovery phase, we
selected five serum samples from four different groups:
controls, asymptomatic AOPD, symptomatic nontreated
AOPD and symptomatic AOPD-treated patients. For the
validation phase, we used samples from 10 healthy con-
trol and 35 Pompe patients.
Discovery phase
miRNAs were measured by qPCR using Serum/Plasma
Focus microRNA PCR 384 wells Panels, (V4.M) (EXI-
QON). Results were analyzed with software available
online by Applied Biosystems (SDS 2.4). Mean and SD
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were calculated and a statistical analysis of the raw data
was performed by ANAXOMICS, a consulting company
expert in the analysis of miRNA data. The relative levels
of selected serum miRNAs were normalized by using cel-
miR-39-3p and Unisp6 as spike-in18 and the miRNAs
has-miR-126-3p, has-miR-151a-3p, and has-miR-21-5p
were identified by applying the geNorm algorithm19, a
pair-wise stability-based method previously described.20
Validation phase
The miRNAs identified in the discovery phase were subse-
quently studied in the validation phase. Although miR-
206 was not included in the panels used for the discovery
phase but was also included in this phase because it is
one of the already described dystromirs, together with
miR-1-3p and miR-133a-3p.21 miR-126-3p was used as
an endogenous normalizer. ExiLENT SYBR Green master
mix (QIAGEN, Venlo, Netherlands) and miRCURY LNA
miRNA PCR Assays (QIAGEN) to study each miRNAs.
We studied 21 miRNA: 14 problem miRNAs, one nor-
malizer, two hemolysis controls and four exogenous con-
trols. Relative miRNA expression was analyzed using
comparative Ct method with the SDS 2.4 software.22
Analysis of miRNA expression in muscle
We analyzed the expression levels of miRNAs in muscles
obtained from AOPD patients (n = 4) and healthy con-
trols (n = 5). Muscle miRNAs were isolated using
DANAGENE microRNA Kit (DANAGEN). For this tech-
nique, we also used MS2 (MS2 RNA, Roche) and exoge-
nous controls for the RNA isolation. For miRNA
expression analysis, ExiLENT SYBR Green master mix
(QIAGEN) and different miRCURY LNA miRNA PCR
Assays (QIAGEN) were used for each of the miRNAs.
We used U6 snRNA (RNU6-2) as an endogenous con-
trol to normalize the data.23
Muscle function tests
The following muscle function tests were performed:
6 min walking test (6MWT), time to walk 10 meters,
timed up-and-go test, time to climb up and down four
steps, and motor function measure-20 items scale (MFM-
20). Muscle strength was studied using both MRC and
hand-held myometry. ACTIVLIM, INQoL, and SF-36
were used as patient reported outcome measures. Forced
vital capacity seated and in lying position was obtained
with a spirometer Carefusion Microlab ML 3500 MK8
(Carefusion, Yorba Linda, CA, USA).
Muscle imaging
All patients were examined in a Philips Achieva XR 1.5
Teslas located at HSCSP. Three-dimensional 3-point
Dixon images were acquired and ROIs were manually
drawn in the areas of interest as previously described10.
Mean thighs fat fraction was calculated from the data
acquired and used for the statistical analysis.
Data analysis
Discovery phase
ANOVA tests were performed to identify differences in
miRNA expression levels between cohorts. P-values
were adjusted for multiple testing using Tukey-Kramer
correction. Dataset with all the variables from the
individual patients was analyzed using a data science
strategy based on data mining approach, in which, the
following methods were used: as feature selection and
extraction algorithms CHOW-LIU, MRMR, RELIEFF,
RFE-SVM, SFFS, and Wilcoxon with correlation and
as the base classifier GLM_Binomal and Na€ıve
Bayes.24–29 In order to prioritize the generalization
capability of the conclusion, a K-fold validation analy-
sis was performed, yielding cross-validated quality
measures (such as accuracy) for each biomarker. The
study was carried out with and without imputed miss-
ing values. The imputation method applied used the
k-nearest neighbor averaging, using Euclidean metric
in the space of each miRNA by cohort to impute the
missing values elements.18
Validation phase
We used nonparametric tests for the statistical analysis of
the variables. We used the Mann–Whitney U test to
investigate whether there were significant differences in
the variables between groups (asymptomatic vs symp-
tomatic/controls vs Pompe).
Clinical correlation
We used Spearman’s rank correlation (coefficient
reported as) to investigate whether there was a correlation
between serum miRNA expression and the clinical results.
As we run multiple correlations, a Bonferroni test was
performed to avoid type 1 error. The results of all statisti-
cal studies were considered significant if P was lower than
0.05. Statistical studies were performed using IBM SPSS
Statistics software version 21.
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Results
Description of the cohort
We included in the study 35 AOPD patients. Thirty
patients were symptomatic and five were asymptomatic.
Twenty-one out of the 30 symptomatic patients were
already receiving ERT when the first sample was obtained.
In the remaining nine symptomatic patients, blood sam-
ples were obtained before ERT was started. Demographic
and clinical data of the patients are described in Table 1.
We also included samples from 10 age and sex-matched
controls.
miRNA expression in the discovery phase
We observed different expression levels between the
groups of study in nine of the 185 miRNAs included in
the discovery assay (ANOVA, P < 0.05). Expression levels
of these nine miRNAs were further analyzed in the valida-
tion phase. These miRNAs included: miR-106b-5p, miR-
199a-5p, miR-652-3p, miR-423-5p, miR-1-3p, miR-133a-
3p, miR-186-5p, miR-338-3p, and miR-23a-3p. We also
included in the validation phase a group of miRNAs that
have been involved in the muscle degeneration process:
miR-206, miR-145-5p, miR-181-5p, miR-486 and miR-
29a-3p.21
miRNA expression in the validation phase
We observed a statistically significant increase in the con-
centration of miR-1-3p and miR-206 between AOPD
patients and controls (Mann–Whitney U test, P < 0.05)
(Fig. 1A and C). We also analyzed if there were differ-
ences between the different subgroups of study: asymp-
tomatic AOPD, symptomatic nontreated AOPD,
symptomatic-treated AOPD and controls. We observed
significant differences between symptomatic-treated
AOPD patients and controls in the expression of miR-1-
3p, miR-133a-3p and miR-206 (Mann–Whitney U test,
P < 0.05), (Fig. 1). In miR-206, we also observed
significant differences between asymptomatic and symp-
tomatic-treated AOPD patients (Mann–Whitney U test,
P < 0.05) (Fig. 1C). Although we identified other poten-
tial miRNAs in the discovery phase none of them showed
significant differences in the validation phase (Fig. 2).Nor-
malized relative expression levels of serum miRNAs in
Pompe patients. Data are presented as mean  SD.
Mann–Whitney U test.
Expression of dystromirs in the progression
of the disease
We decided to study if starting ERT treatment modified
serum levels of dystromirs (miR-1-3p, miR-133a-3p and
miR-206). We studied samples for three patients that
were obtained before and 6 months to 1 year after start-
ing ERT treatment. Dystromirs serum levels increased in
two patients while they decreased in one of the patients
(Fig. 3). However, we did not apply any statistical study
due to the small size of our cohort.
miRNA expression in muscle
We observed a statistically significant increase in the con-
centration of miR-206 in muscle biopsies from AOPD
patients taken before the treatment was started (n = 4)
compared to controls (n = 5) (Fig. 4C). Although the dif-
ferences observed in miR-1-3p and miR-133a-3p muscle
expression were not statistically significant, there was a
trend to be increased in patients compared to controls
(Fig. 4A and B).
Correlations between clinical features and
miRNAs serum levels
We identified a statistically significant correlation between
serum levels of miR-1-3p, miR-133a-3p, and miR-206a in
AOPD patients (Spearman test, P < 0.05 (Table 2). We
also investigated if there were correlations between serum
levels dystromirs and clinical features of the patients. We
did not identify any correlation between age at study, age
Table 1. Clinical characteristics of the control group and the Pompe patients included in the study. Mean and standard deviation are provided
for the quantitative variables.
Clinical characteristics Control n = 10 Asymptomatic n = 5 Nontreated n = 9 Treated n = 21
Age 41.2  16.4 24  8.2 50.6  11.4 50.81  8.6
Sex (male/female) 6/4 2/3 6/3 7/15
Time from onset of symptoms – – 9.4  6.6 15  9.1
Time on ERT – – – 5.1  2.5
Aids for walking – – 0 10
Ventilation – – 2 9
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at start of ERT, time on ERT or delay in the start of
ERT, and serum levels of miRNAs. In contrast, we identi-
fied significant correlations (Spearman test, P < 0.05)
between dystromirs’ serum levels and some of the muscle
function tests (Table 2). However, the correlation coeffi-
cients were lower than 0.6. There was a correlation
between mean thighs fat fraction analyzed using quantita-
tive muscle MRI and miR-206 serum levels, although as it
happened with muscle function tests, the correlation coef-
ficient was lower than 0.
Discussion
The aim of this work was to study miRNA profiles in
Pompe disease patients and evaluate their role as potential
biomarkers. We studied the expression of 190 miRNAs in
AOPD patients and controls and we found increased
expression levels in AOPD patients in three miRNAs:
miR-1-3p, miR-133a-3p, and miR-206. These differences
were more robust when we compared serum levels of
symptomatic patients with controls. Moreover, serum
levels of miR-206 were higher in symptomatic than
presymtomatic patients, suggesting that it could be a valid
biomarker of disease progression. Despite this finding, we
identified weak correlations between muscle function tests
and serum levels of miRNAs.
Several reports have demonstrated that miRNAs are
potential biomarkers of different diseases, such as cancer,
liver injury, or heart failure.30–32 The expression profile of
miRNAs has also been studied in different muscle diseases
such as DMD, myotonic dystrophy, and FSHD.16,33–36 In
these studies, several miRNAs have a different pattern of
expression when compared to controls. Three of them,
the miR-1-3p, miR-133a-3p and miR-206, are persistently
increased in muscular dystrophies and for this reason are
known as dystromirs. Dystromirs are only expressed by
heart and skeletal muscle and, therefore, they can poten-
tially be a valuable tool to follow muscle pathology in
patients with muscle disorders. The function of dystro-
mirs in the process of muscle degeneration and regenera-
tion has been investigated. While miR-133 enhances
proliferation of myoblasts, miR-1 and miR-206 promote
differentiation from myoblasts to myotubes. Dystromirs
expression is regulated by MyoD, Myf5, MEF2, SRF, and
other transcription factors involved in muscle develop-
ment.37,38 The process of muscle degeneration in Pompe
disease is not completely understood. Reduced expression
of alpha-glucosidase leads to a progressive accumulation
of glycogen inside the lysosomes of muscle fibers disrupt-
ing the physiologic process of autophagy. As a result,
glycogen charged lysosomes and autophagic vesicles are
found in the sarcoplasm, disrupting the contractile prop-
erties of skeletal muscle fibers. Eventually, the muscle
fiber dies and is replaced by fat and fibrous tissue resem-
bling what happens in muscle dystrophies. In view of this
fact, it is reasonable to find increased serum levels of dys-
tromirs in AOPD patients, as happens in other muscle
dystrophies, reinforcing the idea that Pompe disease and
muscle dystrophies may share a pathologic process of
muscle degeneration.
As dystromirs are related with the muscle regeneration
process, it is not surprising that they are increased in
muscle disorders, especially in those patients in whom the
process of muscle degeneration is active. We observed
that dystromirs were more expressed in symptomatic than
asymptomatic AOPD patients. Specifically, the expression
of miR-206 was significantly higher in serum samples of
symptomatic compared to asymptomatic AOPD patients.
Therefore, miR-206 serum levels may have a role as a
potential biomarker to follow-up presymptomatic patients
Figure 1. Normalized relative expression levels of validated serum miRNAs in Pompe patients. Data are presented as mean  SD. Mann–Whitney
U test *P < 0.05, **P < 0.01 and ***P < 0.001.
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Figure 2. Normalized relative expression levels of serum miRNAs in Pompe patients. Data are presented as mean  SD. Mann–Whitney U test.
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Figure 4. Normalized relative expression levels of muscle miRNAs in Pompe patients. Data are presented as mean  SD. Mann–Whitney U test
*P < 0.05.
Table 2. Correlation between microRNAs serum levels and clinical features.
miR-1-3p miR-133a-3p miR-206
Sig CC Sig CC Sig CC
miR-1-3p – – 0.007 0.457** 0 0.761**
miR-133a-3p 0.007 0.457** – – 0.003 0.493**
miR-206 0.000 0.761** 0.003 0.493** – –
MRC score 0.089 – 0.094 – 0.035 0.385*
Myometry score 0.899 – 0.803 – 0.337 –
6MWT 0.803 – 0.073 – 0.584 –
Time to walk 10 m 0.514 – 0.043 0.378* 0.151 –
Timed up-and-go test 0.446 – 0.061 – 0.589 –
Time to climb up 4 steps 0.386 – 0.053 – 0.119 –
Time to climb down 4 steps 0.855 – 0.12 – 0.211 –
MFM-20 0.388 – 0.039 0.373* 0.064 –
CVF seated 0.465 – 0,025 0.416* 0.243 –
CVF lying 0.286 – 0.057 – 0.535 –
Activlim 0.628 – 0.986 – 0.462 –
qMRI fat fraction 0.107 – 0.205 – 0.013 0.420*
Sig, bilateral significance; CC, correlation coefficient.
*Spearman Rho test P < 0.05.
**Spearman Rho test P < 0.01.
Figure 3. Dystromir expression changes in Pompe patients in response to the treatment. Data are presented as fold change values in post-ERT
patients regarding their pre-ERT samples.
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over the years in order to identify patients in whom the
process of muscle degeneration has started and are at risk
of developing symptoms of muscle weakness. We did not
observe differences in the serum levels of dystromirs
between treated and nontreated symptomatic patients.
However, a higher number of patients should be analyzed
to draw conclusions on the effect of ERT on the muscle
regeneration process in symptomatic Pompe disease. ERT
has been shown to decrease glycogen accumulation in
muscle fibers of preclinical animal models of the disease
and also in patients. However, recent studies demonstrate
that muscle weakness of treated AOPD patient progresses
despite the treatment and that muscle fatty replacement,
which is related to muscle degeneration process, increases
over the years.9,10 Our finding supports that the process
of muscle degeneration remains active despite the starting
of the treatment in Pompe patients. In accordance, we
did not observe a significant reduction in miRNA expres-
sion levels in serum samples obtained before and after the
treatment. Recently, Tarallo et al studied the profile of
miRNAs in Pompe disease and observed high expression
levels of miR-133a-3p both in IOPD and AOPD
patients.39 These results are in accordance with our inves-
tigations, and suggest that miRNAs could be potential
biomarkers of Pompe disease.
Other miRNAs have a role in skeletal muscle home-
ostasis both in health and in disease-regulating myogene-
sis, muscle atrophy or structural and metabolic changes
related to aging or exercise21. These miRNAs include
miR-23a, miR-29, miR-146a, miR-486, and miR-181
among others. We have studied serum expression levels
of these miRNAs, but we did not find significant differ-
ences between AOPD patients and controls. However,
although our cohort included 35 patients, it is possible
that higher number of samples are needed to identify sub-
tle changes in miRNA expression in serum. In this sense,
analysis of miRNA expression using skeletal muscle biop-
sies should show higher differences. Nevertheless, muscle
biopsies of patients are not always available. We studied
miRNA expression of muscle biopsies and we confirmed
higher expression levels of miR-206 in AOPD patients
than in controls. Although miR-1-3p and miR-133a-3p
levels were increased in AOPD muscle biopsies, we did
not find significant differences with controls, mainly due
to a high variability of miRNA expression.
In conclusion, we have identified a group of miR-
NAs with increased levels of expression in blood sam-
ples of patients with Pompe disease. The role of these
miRNAs in muscle regeneration has been previously
reported and suggests that there is a common patho-
logical pathway between Pompe disease and muscle
dystrophies.
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